Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Helius Medical Technologies, Inc. (26HA.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.3400-0.0080 (-2.30%)
At close: 08:13AM CET
Advertisement

Helius Medical Technologies, Inc.

642 Newtown Yardley Road
Suite 100
Newtown, PA 18940
United States
215 944 6100
https://heliusmedical.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Mr. Dane Carl AndreeffPres, CEO & Director289.4kN/A1966
Mr. Jeffrey S. Mathiesen CPA, CPACFO, Treasurer, Sec. & Director264.33kN/A1961
Dr. Antonella Favit-Van Pelt M.D., Ph.D.Chief Medical Officer221.37kN/A1967
Mr. Lawrence PiccianoSr. VP of Engineering, Quality & Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Corporate Governance

Helius Medical Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement